HealthcareServices

Global Minimal Residual Disease Industry Insights: Key Trends and Growth Estimates

February 26, 2026March 4, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the minimal residual disease market from 2026–2035 with trusted insights from The Business Research Company

Across 2026–2030, what is the expected market valuation path of the Minimal Residual Disease Market?

The minimal residual disease market has seen substantial expansion in recent years. Its value is anticipated to climb from $2.01 billion in 2025 to $2.26 billion in 2026, indicating a compound annual growth rate (CAGR) of 12.5%. This historical growth can be linked to an increase in leukemia and lymphoma cases, the wider adoption of flow cytometry testing, the early incorporation of PCR-based MRD detection, a heightened clinical focus on predicting relapse, and the enhanced capabilities of diagnostic laboratories.

The minimal residual disease market size is anticipated to experience significant expansion in the coming years. It is projected to reach $3.57 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 12.2%. This growth over the forecast period is fueled by the rapid development of NGS-based MRD testing, the escalating demand for personalized oncology treatments, the creation of ultra-sensitive molecular assays, the broader embrace of liquid biopsy MRD testing, and increasing investment in cancer diagnostics research. Prominent trends for this period encompass the adoption of precision medicine in MRD detection, the integration of AI to enhance sensitivity in MRD testing, the expansion of cloud-based data management for MRD monitoring, IoT-enabled connectivity within MRD diagnostic platforms, and the automation and digitalization of laboratory MRD analysis.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21224&type=smp

Which Drivers Are Supporting The Rise Of The Minimal Residual Disease Market?

The rising incidence of cancer is anticipated to drive expansion in the minimal residual disease market going forward. Cancer is a condition marked by the uncontrolled multiplication and spread of irregular cells within the body. The escalating occurrence of cancer is attributed to factors like an aging demographic, increased exposure to environmental carcinogens, unhealthy lifestyles, and genetic predispositions. This increasing cancer burden necessitates accurate MRD testing to identify remaining cancer cells, thereby facilitating prompt intervention and personalized treatment. This approach improves the ability to predict relapse and enhances patient outcomes. For instance, in February 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, more than 35 million new cancer cases were projected by 2050, signifying a 77% rise compared to the estimated 20 million cases in 2022. Consequently, the growing prevalence of cancer is a key factor propelling the minimal residual disease market.

What Leading Segments Are Studied In The Minimal Residual Disease Market?

The minimal residual disease market covered in this report is segmented –

1) By Detection Target: Lymphoma, Leukemia, Solid Tumors, Other Detection Targets

2) By Test Technique: Flow Cytometry, Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Other Test Techniques

3) By End-User: Hospitals, Diagnostic Laboratories, Research Institutions

Subsegments:

1) By Lymphoma: Hodgkin Lymphoma, Non-Hodgkin Lymphoma

2) By Leukemia: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia

3) By Solid Tumors: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer

4) By Other Detection Targets: Multiple Myeloma, Neuroblastoma, Sarcomas

What Trends Are Projected To Support The Growth Of The Minimal Residual Disease Market?

Leading companies operating within the minimal residual disease (MRD) market are concentrating on developing advanced ultra-sensitive assays to improve early detection and patient management. These ultra-sensitive assays are laboratory tests specifically designed to identify circulating tumor DNA at exceptionally low frequencies with high accuracy, facilitating earlier discovery of cancer recurrence and enhancing treatment decisions. As an illustration, in April 2025, Natera, Inc., a US-based provider of cell-free DNA and genetic testing, introduced the Signatera Genome MRD test. This test features a personalized, tumor-informed assay created from a patient’s whole genome sequence and matched normal DNA. The test employs multiplex polymerase chain reaction and next-generation sequencing technology to detect tumor DNA at frequencies as low as 1 part per million and below for research applications. Its clinical validity has been confirmed across several cancer types, including breast, colorectal, non-small cell lung, melanoma, and renal cell carcinoma. Signatera Genome helps identify postsurgical patients who face a higher risk of recurrence, offers predictive clinical utility, supports both clinical and research uses, and has coverage from Medicare for a wide array of indications, thereby enabling more precise and informed treatment strategies.

Which Major Industry Participants Are Leading The Minimal Residual Disease Market Growth?

Major companies operating in the minimal residual disease market are Thermo Fisher Scientific Inc., LabCorp, Quest Diagnostics Incorporated, Agilent Technologies Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Natera Inc., Foundation Medicine Inc., NeoGenomics Inc., Guardant Health Inc., Adaptive Biotechnologies Corporation, Invivoscribe Inc., Mission Bio Inc., ArcherDx Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd., Illumina Inc., Personalis Inc., Asuragen Inc., ARUP Laboratories Inc., Myriad Genetics Inc., Luminex Corporation, EntroGen Inc., 3B BlackBio Biotech India, Bioartis, PerkinElmer Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/minimal-residual-disease-global-market-report

Which Region Currently Holds The Largest Share Of The Minimal Residual Disease Market?

North America was the largest region in the minimal residual disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the minimal residual disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Minimal Residual Disease Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21224&type=smp

Browse Through More Reports Similar to the Global Minimal Residual Disease Market 2026, By The Business Research Company

Rare Neurological Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-neurological-disease-treatment-global-market-report

Rare Disease Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-disease-diagnostics-global-market-report

Rare Diseases Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-diseases-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795